About Dr. Chavez

Julio Chavez, MD

About Dr. Chavez

Dr. Chavez is a dedicated physician specializing in lymphoid malignancies at Moffitt Cancer Center, where he serves as an Associate Member in the Lymphoma Section within the Department of Malignant Hematology. He obtained his medical degree from Universidad Peruana Cayetano Heredia in Lima, Peru, and completed his hematology residency at Hospital Edgardo Rebagliati Martins in collaboration with the same university. His training continued in the United States, where he pursued an Internal Medicine residency at the State University of New York in Buffalo, followed by a Medical Oncology fellowship at the University of South Florida/Moffitt Cancer Center.

Board-certified in both Internal Medicine and Medical Oncology, Dr. Chavez has a strong clinical and research focus on aggressive lymphomas, virally associated lymphoid malignancies, and chronic lymphocytic leukemia. Additionally, he has a keen interest in treating acute lymphoblastic leukemia in elderly patients. As a principal investigator in multiple clinical trials, he actively explores the use of targeted therapies and immunotherapy to advance treatment options. His expertise extends beyond standard therapies, allowing him to provide patients with innovative, individualized treatment plans based on the latest research. Since joining Moffitt Cancer Center in 2013, Dr. Chavez has remained committed to improving outcomes for patients through both cutting-edge research and personalized care.

Articles by Julio Chavez, MD

Ruemu Birhiray, MDFollicular Lymphoma | March 4, 2025
With insights into next-generation therapies, this discussion explores what’s ahead in the follicular lymphoma landscape.
Ruemu Birhiray, MDFollicular Lymphoma | March 4, 2025
Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on FL treatment.
Ruemu Birhiray, MDFollicular Lymphoma | March 4, 2025
Three experts analyze data on combination therapy for FL, including efficacy, safety, and strategy adoption.